为维护中华医学会系列杂志的声誉和广大读者的利益,现将中华医学会对一稿两投和一稿两用问题的处理声明如下:l)本声明中所涉及的文稿均指原始研究的报告或尽管2篇文稿在文字的表达和讨论的叙述 To safeguard the reputation of the Chinese Medical Association series of magazines and the interests of readers, the Chinese Medical Association is now on the treatment of a two manuscript and a manuscript dual-use issues are as follows: l) The statements involved in the draft refer to the original study Report or narrative despite the presentation of 2 articles in the text and discussion